Komatsu H, Amano M
Yoshitomi Pharmaceutical Industries, Ltd, Fukuoka, Japan.
Int J Immunopharmacol. 1997 Nov-Dec;19(11-12):661-7. doi: 10.1016/s0192-0561(97)00110-0.
Y-24180 ((+/-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dim eth yl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4] diazepine), an antagonist of platelet-activating factor (PAF) receptor, has already been reported to inhibit leukotriene B4 (LTB4)-induced activation of polymorphonuclear leukocytes. In this article, to clarify the mechanism of inhibition of LTB4-induced activation by Y-24180, we examined the effect of Y-24180 on LTB4-induced increase in intracellular calcium ion ([Ca2+]i) level of human polymorphonuclear leukocytes at a single cell level using a laser scanning confocal microscope. Preincubation with Y-24180 significantly inhibited the increase in [Ca2+]i level at 0.3-3 microM, while WEB 2086 (4-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a ][1,4]diazepin-2-yl]propionyl]morpholine), another PAF receptor antagonist, did not show the inhibitory effect at 3-30 microM, indicating that the difference in potency between these compounds was more than 100-fold. The LTB4-induced increase in [Ca2+]i level was suppressed by microinjection of anti-PAF antibody, but not control antibody, into leukocytes. Microinjection of Y-24180 at 0.003-0.03 microM or WEB 2086 at 0.03-0.3 microM into leukocytes also inhibited the LTB4-induced increase. The microinjection of WEB 2086 at the 10-fold greater concentrations than those of Y-24180 inhibited to the almost equal level to that obtained by Y-24180. In addition, microinjection of PAF into leukocytes induced the increase in [Ca2+]i level. Preincubation with Y-24180 at 1 or 3 microM significantly attenuated the PAF microinjection-induced increase, but WEB 2086 showed little effect at 3-30 microM. These results indicate that Y-24180 inhibits LTB4-induced activation of leukocytes by suppressing the increase in [Ca2+]i level and the inhibitory effect is mediated by antagonistic action against intracellular PAF-induced up-regulation of [Ca2+]i level. The difference in inhibitory activity for the increase in [Ca2+]i level between Y-24180 and WEB 2086 when these are added in the culture medium may depend upon their aptitude for the transmembrane influx.
Y - 24180((±)-4-(2 - 氯苯基)-2-[2-(4 - 异丁基苯基)乙基]-6,9 - 二甲基 - 6H - 噻吩并[3,2 - f][1,2,4]三唑并[4,3 - a][1,4]二氮杂䓬),一种血小板活化因子(PAF)受体拮抗剂,已被报道可抑制白三烯B4(LTB4)诱导的多形核白细胞活化。在本文中,为阐明Y - 24180抑制LTB4诱导活化的机制,我们使用激光扫描共聚焦显微镜在单细胞水平上研究了Y - 24180对LTB4诱导的人多形核白细胞细胞内钙离子([Ca2 +]i)水平升高的影响。用Y - 24180预孵育在0.3 - 3 microM时显著抑制了[Ca2 +]i水平的升高,而另一种PAF受体拮抗剂WEB 2086(4 - [3 - [4 - (2 - 氯苯基)-9 - 甲基 - 6H - 噻吩并[3,2 - f][1,2,4]三唑并[4,3 - a][1,4]二氮杂䓬 - 2 - 基]丙酰基]吗啉)在3 - 30 microM时未显示出抑制作用,表明这些化合物之间的效价差异超过100倍。将抗PAF抗体而非对照抗体显微注射到白细胞中可抑制LTB4诱导的[Ca2 +]i水平升高。将0.003 - 0.03 microM的Y - 24180或0.03 - 0.3 microM的WEB 2086显微注射到白细胞中也抑制了LTB4诱导的升高。以比Y - 24180高10倍的浓度显微注射WEB 2086时,其抑制水平与Y - 24180几乎相同。此外,将PAF显微注射到白细胞中可诱导[Ca2 +]i水平升高。用1或3 microM的Y - 24180预孵育可显著减弱PAF显微注射诱导的升高,但WEB 2086在3 - 30 microM时几乎没有作用。这些结果表明,Y - 24180通过抑制[Ca2 +]i水平升高来抑制LTB4诱导的白细胞活化,并且这种抑制作用是由对细胞内PAF诱导的[Ca2 +]i水平上调的拮抗作用介导的。当Y - 24180和WEB 2086添加到培养基中时,它们对[Ca2 +]i水平升高的抑制活性差异可能取决于它们的跨膜内流能力。